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Dear editor,
We described three critically ill patients with coronavirus disease 2019 in Wuhan, China, featured with profound inflammation and treated with blood purification therapies, including plasma exchange and adso rption. Potential effect in managing cytokine storm and pathogenic antibodies was shown. This added to the limited therapeutic options in these patients, and more efforts are proposed to further prove the benefits.
During the ongoing outbreak of COVID-19, 5-6% of the patients need ICU admission or even mechanical ventilation due to severe respiratory failure, with the mortality increasing from 1.4% to over 60% (1, 2) . Non-survivors, with profound hypoxia and inflammatory response, are more likely to develop acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (2, 3) . Additionally, reduced peripheral lymphocytes, high levels of C-reactive protein (CRP) and IL-6, and significantly abnormal coagulation parameters are hallmarks in those severe cases (4, 5) . Emerging evidence indicates the potential benefits of managing cytokine storm, via using steroid or IL-6/IL-6-receptor blocking antibodies (3, 6) . The capability of blood purification therapy in removing pathogenic antibodies or cytokines has been proven in multiple scenarios, but not in COVID-19 patients (7, 8) . Our knowledge of critically ill COVID-19 in the late phase was quite limited. These cases highlight the presence of cytokine storm or pathogenic antibodies afte r three weeks of COVID-19 onset (Figure 1 ), which correlated with the disease severities.
Monitoring inflammation and antibodies are important especially in patients infected by virus with persistent fever or abnormal coagulopathy. Expeditious control of t he cytokine storm in early phase might be beneficial to selective patients, and blood purification therapy is effective in our limited experiences. The therapies are tolerable to most patients if performed with the assistance of nephrology specialists, in order to J o u r n a l P r e -p r o o f Journal Pre-proof minimize risks of infection and bleeding. Although randomized trial data is lacking, we propose that multi-disciplinary efforts should be made to maximize the availability of blood purification therapy to proper patients.
